Blueprint Medicines Co. (NASDAQ:BPMC) CEO Sells $159,407.04 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The shares were sold at an average price of $96.60, for a total value of $227,299.80.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $114.91 on Friday. The firm has a market cap of $7.30 billion, a P/E ratio of -54.46 and a beta of 0.61. The firm’s 50-day simple moving average is $95.80 and its 200-day simple moving average is $95.33. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the business earned ($2.20) earnings per share. The company’s quarterly revenue was up 126.5% on a year-over-year basis. As a group, research analysts expect that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on BPMC shares. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a report on Monday, January 13th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wells Fargo & Company lowered their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.72.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BPMC. Amalgamated Bank grew its holdings in shares of Blueprint Medicines by 5.3% in the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 109 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Blueprint Medicines by 12.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,276 shares of the biotechnology company’s stock valued at $461,000 after buying an additional 485 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Blueprint Medicines during the second quarter worth about $1,060,000. Sei Investments Co. increased its holdings in shares of Blueprint Medicines by 15.4% during the second quarter. Sei Investments Co. now owns 52,986 shares of the biotechnology company’s stock worth $5,711,000 after buying an additional 7,073 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Blueprint Medicines in the second quarter valued at approximately $7,458,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.